UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

 

SEC FILE NUMBER

0-28666

 

CUSIP NUMBER

024600

 

(Check One):

☐

Form 10-K

☐

Form 20-F

☐

Form 11-K

☒

Form 10-Q

☐

Form 10-D

☐

Form N-SAR

 

☐

Form N-CSR

 

 

 

 

 

For period ended September 30, 2022

 

 

☐

Transition Report on Form 10-K

 

☐

Transition Report on Form 20-F

 

☐

Transition Report on Form 11-K

 

☐

Transition Report on Form 10-Q

 

☐

Transition Report on Form N-SAR

 

 

 

 

For the Transition Period Ended

  

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  Not Applicable

 

PART I - REGISTRANT INFORMATION

 

American Bio Medica Corporation

Full name of registrant

 

Not Applicable 

Former Name if Applicable

 

122 Smith Road

Address of Pincipal Eecutive Ofice (Sreet and Number)

 

Kinderhook, New York 12106 

City, Sate and Zip Code 

 

 

 

  

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed.  (Check box if appropriate)

 

 

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

 

 

☒

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date, or the subject quarterly report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

 

 

 

 

(c)

The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III - NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed.)

 

The registrant is unable to timely file its requisite quarterly report on Form 10-Q for period ended September 30, 2022 by the prescribed due date of November 14, 2022. The registrant need additional time to complete its financial statements and other disclosures in the Form 10-Q. This need for additional time will result in the independent registered public accounting firm needing additional time to complete its review of the financial statements and the Form 10-Q for the quarter ended September 30, 2022.

 

In accordance with Rule 12b-25 promulgated under the Securities and Exchance Act of 1934, as amended, the Registrant intends to file its Form 10-Q on or prior to November 21, 2022.  

 

PART IV - OTHER INFORMATION

 

(1)

Name and telephone number of person to contact in regard to this notification:

 

 

Melissa A. Waterhouse

 

(518)

 

758-8158

 

 

(Name)

 

(Area Code)

 

(Telephone Number)

 

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, please identity report(s).

 

☒ Yes     No ☐ 

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

☐ Yes     No ☒ 

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 
2

 

 

AMERICAN BIO MEDICA CORPORATION

(Name of Registrant as Specified in Charter)

 

Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  November 14, 2022 By: /s/ Melissa A. Waterhouse

 

 

 Melissa A. Waterhouse  
    Chief Executive Officer/ Principal Financial Officer  

 

 
3

                                                      

American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more American Bio Medica (CE) Charts.
American Bio Medica (CE) (USOTC:ABMC)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more American Bio Medica (CE) Charts.